目前，鼻咽癌患者的低生存率和不良预后主要归因于早期和准确的诊断以及对放疗的耐药性的缺乏。与此同时，成像引导诊断和精确治疗的融合在治疗纳米技术领域引起了很大的关注。然而，构建具有理想成像性能和良好生物相容性的双模成像引导纳米治疗仍然具有挑战性。因此，我们开发了一种简单但多功能的纳米治疗剂GdCPP，用于鼻咽癌（NPC）的早期和准确诊断以及有效治疗，将荧光成像和磁共振成像（MRI）结合到单个纳米平台上，用于成像引导下的光动力疗法（PDT）。GdCPP具有适当的粒径（81.93 ± 0.69 nm）和高稳定性，导致足够的肿瘤积累，辐射照射后产生大量的活性氧（ROS），进一步显著杀伤肿瘤细胞。此外，与临床使用的Gd-DTPA（5.034 mM-1 s-1）相比，GdCPP具有更高的r1弛豫度（9.396 mM-1 s-1），并展现出更好的T1WI MRI成像性能。在双模成像引导下的PDT中，GdCPP实现了有效的治疗效果，而不引起明显的组织损伤。体外和体内研究的结果表明，GdCPP可能是适用于双模成像引导的精确肿瘤治疗的合适候选剂。

Currently, the low survival rate and poor prognosis of patients with nasopharyngeal carcinoma are ascribed to the lack of early and accurate diagnosis and resistance to radiotherapy. In parallel, the integration of imaging-guided diagnosis and precise treatment has gained much attention in the field of theranostic nanotechnology. However, constructing dual-modal imaging-guided nanotheranostics with desired imaging performance as well as great biocompatibility remains challenging. Therefore, we developed a simple but multifunctional nanotheranostic GdCPP for the early and accurate diagnosis and efficient treatment of nasopharyngeal carcinoma (NPC), which combined fluorescence imaging and magnetic resonance imaging (MRI) onto a single nanoplatform for imaging-guided subsequent photodynamic therapy (PDT). GdCPP had an appropriate particle size (81.93 ± 0.69 nm) and was highly stable, resulting in sufficient tumor accumulation, which along with massive reactive oxygen species (ROS) generation upon irradiation further significantly killed tumor cells. Moreover, GdCPP owned much stronger r1 relaxivity (9.396 mM-1 s-1) compared to clinically used Gd-DTPA (5.034 mM-1 s-1) and exhibited better T1WI MRI performance. Under dual-modal imaging-guided PDT, GdCPP achieved efficient therapeutic outcomes without causing any noticeable tissue damage. The results of in vitro and in vivo studies indicated that GdCPP may be a suitable candidate for dual-modal imaging-guided precision tumor therapy.